VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 75 filers reported holding VAXCYTE INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,344,405 | +2.1% | 1,007,148 | 0.0% | 1.09% | +19.8% |
| Q2 2023 | $50,296,971 | +84.0% | 1,007,148 | +38.1% | 0.91% | +69.6% |
| Q1 2023 | $27,339,374 | -55.6% | 729,439 | -43.2% | 0.54% | -54.4% |
| Q4 2022 | $61,525,892 | +164.9% | 1,283,126 | +32.6% | 1.18% | +173.1% |
| Q3 2022 | $23,230,000 | -29.5% | 967,900 | -36.1% | 0.43% | -27.8% |
| Q2 2022 | $32,937,000 | -9.9% | 1,513,659 | 0.0% | 0.60% | +0.7% |
| Q1 2022 | $36,555,000 | +40.1% | 1,513,659 | +38.0% | 0.59% | +77.0% |
| Q4 2021 | $26,090,000 | -0.6% | 1,096,700 | +6.0% | 0.34% | +16.3% |
| Q3 2021 | $26,249,000 | +23.3% | 1,034,665 | +9.4% | 0.29% | +34.0% |
| Q2 2021 | $21,281,000 | +66.1% | 945,400 | +45.7% | 0.22% | +79.2% |
| Q1 2021 | $12,813,000 | -23.5% | 648,774 | +2.9% | 0.12% | -18.4% |
| Q4 2020 | $16,746,000 | -47.1% | 630,260 | -1.6% | 0.15% | -63.1% |
| Q3 2020 | $31,641,000 | +17.8% | 640,760 | -24.6% | 0.40% | +5.3% |
| Q2 2020 | $26,869,000 | – | 850,000 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |